{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:46:39Z","timestamp":1761396399263},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,31]]},"DOI":"10.7759\/cureus.30923","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T18:01:00Z","timestamp":1667239260000},"source":"Crossref","is-referenced-by-count":1,"title":["Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report"],"prefix":"10.7759","author":[{"given":"Shahkar","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif M","family":"Elhosseiny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taqi","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Lafferty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2020.101058","article-title":"COVID-19: therapeutics and interventions currently under consideration","volume":"66","author":"McFee RB","year":"2020","unstructured":"McFee RB. COVID-19: therapeutics and interventions currently under consideration. Dis Mon. 2020, 66:10.1016\/j.disamonth.2020.101058","journal-title":"Dis Mon"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of Its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman RT","year":"2020","unstructured":"Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. Remdesivir: a review of Its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020, 6:672-83. 10.1021\/acscentsci.0c00489","journal-title":"ACS Cent Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01814-20","article-title":"New perspectives on antimicrobial agents: remdesivir treatment for COVID-19","volume":"65","author":"Aleissa MM","year":"2020","unstructured":"Aleissa MM, Silverman EA, Acosta LM, Nutt CT, Richterman A, Marty FM. New perspectives on antimicrobial agents: remdesivir treatment for COVID-19. Antimicrob Agents Chemother. 2020, 65:10.1128\/AAC.01814-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner CD","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, et al.. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020, 324:1048-57. 10.1001\/jama.2020.16349","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2020.198137","article-title":"Effect of remdesivir on patients with COVID-19: a network meta-analysis of randomized control trials","volume":"288","author":"Yokoyama Y","year":"2020","unstructured":"Yokoyama Y, Briasoulis A, Takagi H, Kuno T. Effect of remdesivir on patients with COVID-19: a network meta-analysis of randomized control trials. Virus Res. 2020, 288:10.1016\/j.virusres.2020.198137","journal-title":"Virus Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2021.e01254","article-title":"Remdesivir therapy causing bradycardia in COVID-19 patients: two case reports","volume":"26","author":"Abdelmajid A","year":"2021","unstructured":"Abdelmajid A, Osman W, Musa H, Elhiday H, Munir W, Al Maslamani MA, Elmekaty EZ. Remdesivir therapy causing bradycardia in COVID-19 patients: two case reports. IDCases. 2021, 26:10.1016\/j.idcr.2021.e01254","journal-title":"IDCases"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19919","article-title":"Bradycardia related to remdesivir during COVID-19: persistent or permanent?","volume":"13","author":"Maheshwari M","year":"2021","unstructured":"Maheshwari M, Athiraman H. Bradycardia related to remdesivir during COVID-19: persistent or permanent?. Cureus. 2021, 13:10.7759\/cureus.19919","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results","volume":"384","author":"Pan H","year":"2021","unstructured":"Pan H, Peto R, Henao-Restrepo AM, et al.. Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results. N Engl J Med. 2021, 384:497-511. 10.1056\/NEJMoa2023184","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19 - final report","volume":"383","author":"Beigel JH","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al.. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med. 2020, 383:1813-26. 10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu S","year":"2019","unstructured":"Mulangu S, Dodd LE, Davey RT Jr, et al.. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019, 381:2293-303. 10.1056\/NEJMoa1910993","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ph14070611","article-title":"Cardiac events potentially associated to remdesivir: an analysis from the European Spontaneous Adverse Event Reporting System","volume":"14","author":"Rafaniello C","year":"2021","unstructured":"Rafaniello C, Ferrajolo C, Sullo MG, et al.. Cardiac events potentially associated to remdesivir: an analysis from the European Spontaneous Adverse Event Reporting System. Pharmaceuticals (Basel). 2021, 14:10.3390\/ph14070611","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2021-141079","article-title":"Bradycardia during remdesivir treatment might be associated with improved survival in patients with COVID-19: a retrospective cohort study on 473 patients from a tertiary centre","volume":"98","author":"Bistrovic P","year":"2022","unstructured":"Bistrovic P, Manola S, Lucijanic M. Bradycardia during remdesivir treatment might be associated with improved survival in patients with COVID-19: a retrospective cohort study on 473 patients from a tertiary centre. Postgrad Med J. 2022, 98:501-2. 10.1136\/postgradmedj-2021-141079","journal-title":"Postgrad Med J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2020.08.025","article-title":"Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review","volume":"2","author":"Gubitosa JC","year":"2020","unstructured":"Gubitosa JC, Kakar P, Gerula C, et al.. Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review. JACC Case Rep. 2020, 2:2260-4. 10.1016\/j.jaccas.2020.08.025","journal-title":"JACC Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.05.025","article-title":"Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19)","volume":"83","author":"Pallotto C","year":"2021","unstructured":"Pallotto C, Blanc P, Esperti S, et al.. Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19). J Infect. 2021, 83:237-79. 10.1016\/j.jinf.2021.05.025","journal-title":"J Infect"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.12.017","article-title":"Remdesivir-associated bradycardia might be a sign of good prognosis in COVID-19 patients","volume":"28","author":"Lucijanic M","year":"2022","unstructured":"Lucijanic M, Bistrovic P. Remdesivir-associated bradycardia might be a sign of good prognosis in COVID-19 patients. Clin Microbiol Infect. 2022, 28:10.1016\/j.cmi.2021.12.017","journal-title":"Clin Microbiol Infect"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104955","article-title":"Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes","volume":"184","author":"Choi SW","year":"2020","unstructured":"Choi SW, Shin JS, Park SJ, et al.. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. Antiviral Res. 2020, 184:10.1016\/j.antiviral.2020.104955","journal-title":"Antiviral Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27177","article-title":"Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019-the pilot study","volume":"93","author":"Bistrovic P","year":"2021","unstructured":"Bistrovic P, Lucijanic M. Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019-the pilot study. J Med Virol. 2021, 93:5724-5. 10.1002\/jmv.27177","journal-title":"J Med Virol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(01)01604-6","article-title":"Usefulness of T-axis deviation as an independent risk indicator for incident cardiac events in older men and women free from coronary heart disease (the Cardiovascular Health Study)","volume":"88","author":"Rautaharju PM","year":"2001","unstructured":"Rautaharju PM, Nelson JC, Kronmal RA, et al.. Usefulness of T-axis deviation as an independent risk indicator for incident cardiac events in older men and women free from coronary heart disease (the Cardiovascular Health Study). Am J Cardiol. 2001, 88:118-23. 10.1016\/s0002-9149(01)01604-6","journal-title":"Am J Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23700","article-title":"Remdesivir therapy associated with Bradycardia in SARS-CoV2","volume":"44","author":"Kumar S","year":"2021","unstructured":"Kumar S, Arcuri C, Chaudhuri S, Gupta R, Aseri M, Barve P, Shah S. Remdesivir therapy associated with Bradycardia in SARS-CoV2. Clin Cardiol. 2021, 44:1190-1. 10.1002\/clc.23700","journal-title":"Clin Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-021-03940-4","article-title":"Severe sinus bradycardia associated with remdesivir in a child with severe SARS-CoV-2 infection","volume":"180","author":"Sanchez-Codez MI","year":"2021","unstructured":"Sanchez-Codez MI, Rodriguez-Gonzalez M, Gutierrez-Rosa I. Severe sinus bradycardia associated with remdesivir in a child with severe SARS-CoV-2 infection. Eur J Pediatr. 2021, 180:10.1007\/s00431-021-03940-4","journal-title":"Eur J Pediatr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00554.2015","article-title":"Drug-induced mitochondrial dysfunction and cardiotoxicity","volume":"309","author":"Varga ZV","year":"2015","unstructured":"Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015, 309:1453-67. 10.1152\/ajpheart.00554.2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref22","article-title":"Marked self-limiting sinus bradycardia in COVID-19 patients not requiring therapy in the intensive care unit - case series report","volume":"49","author":"Elikowski W","year":"2021","unstructured":"Elikowski W, Ferta\u0142a N, Zawodna-Marsza\u0142ek M, et al.. Marked self-limiting sinus bradycardia in COVID-19 patients not requiring therapy in the intensive care unit - case series report. Pol Merkur Lekarski. 2021, 49:295-302.","journal-title":"Pol Merkur Lekarski"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/120762-permanent-pacemaker-placement-secondary-to-remdesivir-induced-bradycardia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:48Z","timestamp":1707508008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/120762-permanent-pacemaker-placement-secondary-to-remdesivir-induced-bradycardia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.30923","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,31]]}}}